Follow
Siraj Ali
Siraj Ali
Humanity
Verified email at eqrx.com
Title
Cited by
Cited by
Year
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov, DA Guertin, SM Ali, DM Sabatini
Science 307 (5712), 1098-1101, 2005
82662005
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim, DD Sarbassov, SM Ali, JE King, RR Latek, ...
Cell 110 (2), 163-175, 2002
36872002
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov, SM Ali, DH Kim, DA Guertin, RR Latek, ...
Current biology 14 (14), 1296-1302, 2004
33902004
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov, SM Ali, S Sengupta, JH Sheen, PP Hsu, AF Bagley, ...
Molecular cell 22 (2), 159-168, 2006
32582006
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9, 1-14, 2017
28792017
Growing roles for the mTOR pathway
DD Sarbassov, SM Ali, DM Sabatini
Current opinion in cell biology 17 (6), 596-603, 2005
20022005
GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR
DH Kim, DD Sarbassov, SM Ali, RR Latek, KVP Guntur, ...
Molecular cell 11 (4), 895-904, 2003
12682003
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
12292018
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Cancer discovery 5 (8), 850-859, 2015
7262015
Calcineurin associated with the inositol 1, 4, 5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux
AM Cameron, JP Steiner, AJ Roskams, SM Ali, GV Ronnettt, SH Snyder
Cell 83 (3), 463-472, 1995
6101995
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study
A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ...
Journal of Clinical Oncology 36 (34), 3353-3360, 2018
5822018
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ...
Annals of Oncology 30 (7), 1096-1103, 2019
5462019
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing
JS Ross, K Wang, L Gay, R Al-Rohil, JV Rand, DM Jones, HJ Lee, ...
The oncologist 19 (3), 235-242, 2014
4912014
Targeted next generation sequencing identifies markers of response to PD-1 blockade
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
4672016
Diverse and targetable kinase alterations drive histiocytic neoplasms
EL Diamond, BH Durham, J Haroche, Z Yao, J Ma, SA Parikh, Z Wang, ...
Cancer discovery 6 (2), 154-165, 2016
4342016
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ...
Journal of Thoracic Oncology 11 (9), 1493-1502, 2016
3752016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ...
The Journal of clinical investigation 126 (6), 2334-2340, 2016
3612016
Biliary cancer: utility of next‐generation sequencing for clinical management
M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley, K Wang, HC Kang, ...
Cancer 122 (24), 3838-3847, 2016
3562016
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
SM Lim, HR Kim, JS Lee, KH Lee, YG Lee, YJ Min, EK Cho, SS Lee, ...
Journal of clinical oncology 35 (23), 2613-2618, 2017
3472017
Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer
JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ...
Journal of Clinical Oncology 35 (23), 2624, 2017
3452017
The system can't perform the operation now. Try again later.
Articles 1–20